1-苯并噻吩-5-基异氰酸酯 | 5376-10-3

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-苯并噻吩-5-基异氰酸酯
• 中文别名: (1-苄基-1H-咪唑-2-基)甲醇
• 英文名称: 1-benzyl-2-(hydroxymethyl)imidazole
• 英文别名: 1-benzyl-2-(hydroxymethyl)-1H-imidazole；(1-benzyl-1H-imidazol-2-yl)methanol；N-benzyl-2-(hydroxymethyl)imidazole；1-Benzyl-2-hydroxymethylimidazole；2-hydroxymethyl-N-benzylimidazole；1-benzylimidazole-2-methanol；(1-benzylimidazol-2-yl)methanol
• CAS: 5376-10-3
• 化学式: C₁₁H₁₂N₂O
• mdl: MFCD00174260
• 分子量: 188.229
• InChiKey: SGIKRGDBBXWNRI-UHFFFAOYSA-N

物化性质

• 熔点：
  89-92°C
• 沸点：
  354.9±25.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933290090
• WGK Germany：
  3
• 安全说明：
  S26,S36/37/39

SDS

Name:	(1-Benzyl-1h-imidazol-2-yl)methanol 97% Material Safety Data Sheet
Synonym:	1-Benzyl-2-(hydroxymethyl)imidazol
CAS:	5376-10-3

Section 1 - Chemical Product MSDS Name:(1-Benzyl-1h-imidazol-2-yl)methanol 97% Material Safety Data Sheet
Synonym:1-Benzyl-2-(hydroxymethyl)imidazol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5376-10-3	(1-Benzyl-1H-imidazol-2-yl)methanol, 9	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5376-10-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: pleasant odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 89 - 92 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H12N2O
Molecular Weight: 188

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5376-10-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(1-Benzyl-1H-imidazol-2-yl)methanol, 97% - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 5376-10-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5376-10-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5376-10-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-苯并噻吩-5-基异氰酸酯 在 氯化亚砜 作用下， 生成 1-苄基-2-(氯甲基)-1H-咪唑
  参考文献：
  名称：

  金属酶模型。侧链含羟基咪唑和吡啶的二价金属离子催化水解吡啶甲酸对硝基苯酯

  摘要：

  在不存在和存在二价金属离子（Ni(II)、Zn(II)、Co(II)、Ca、Mg）的情况下，测量了对硝基苯基吡啶甲酸酯在 25 °C 和 6.5-8.5 范围内水解的速率常数)和取代的咪唑或吡啶作为在其侧链中具有醇羟基的配体。在金属离子或配体存在的情况下，速率很慢，准一级速率常数 (kobsd) 相对于金属离子或配体的浓度以一级方式线性增加，直到它给出二级-顺序速率常数，分别为 kM 或 kL。在金属离子（Ni（II）或 Zn（II））和配体同时存在的情况下，一些配体的速率增加显着，kobsd 值的增加构建了关于金属离子或配体浓度增加的饱和曲线.

  DOI：

  10.1246/bcsj.56.1101
• 作为产物：
  描述：

  1-苄基-1H-咪唑-2-甲醛 在 甲醇 、 sodium tetrahydroborate 作用下， 生成 1-苯并噻吩-5-基异氰酸酯
  参考文献：
  名称：

  MUSCARINIC RECEPTOR ANTAGONISTS

  摘要：

  本发明一般涉及公式I的毒蕈碱受体拮抗剂，该拮抗剂可用于治疗通过毒蕈碱受体介导的呼吸道、泌尿道和消化系统的各种疾病，还涉及揭示化合物的制备过程、含有揭示化合物的药物组合物，以及治疗通过毒蕈碱受体介导的疾病的方法。公式（I）中，Het：是杂环烷基或杂芳基X：O、S或NR1，其他取代基如索取权中所定义。

  公开号：

  US20100144801A1
• 作为试剂：
  描述：

  甲酸苄酯 在 1-苯并噻吩-5-基异氰酸酯 作用下， 以 均三甲苯 为溶剂， 反应 27.0h， 生成 benzyl 2-(4-methoxyphenyl)propanoate
  参考文献：
  名称：

  咪唑衍生物作为烯烃催化钌催化的加氢酯化和氨基甲酰化的促进剂：广泛的配体筛选和机理研究

  摘要：

  咪唑衍生物是使用甲酸酯促进[Ru 3（CO）12 ]催化的烯烃加氢酯化反应的有效配体。进行了广泛的配体筛选，以确定2-羟甲基化的咪唑为最佳配体。既不需要一氧化碳气体也不需要引导基团，并且该反应还显示出广泛的底物通用性。Ru-咪唑催化剂体系还促进了分子内的氨基甲酰化作用，以提供内酰胺。通过X射线晶体学分析明确地分析了Ru-咪唑配合物，它具有源自[[Ru 3（CO）12 ]和两个配体的三核结构。该配合物也已成功用于加氢酯化。通过使用D详细检查了该机制－和13 C标记的甲酸酯，表明加氢酯化反应是通过脱羰基－再羰基化途径进行的。

  DOI：

  10.1002/cctc.201402986

文献信息

• Discovery of Functionally Selective 7,8,9,10-Tetrahydro-7,10-ethano-1,2,4-triazolo[3,4-<i>a</i>]phthalazines as GABA_A Receptor Agonists at the α₃ Subunit
  作者：Michael G. N. Russell、Robert W. Carling、John R. Atack、Frances A. Bromidge、Susan M. Cook、Peter Hunt、Catherine Isted、Matt Lucas、Ruth M. McKernan、Andrew Mitchinson、Kevin W. Moore、Robert Narquizian、Alison J. Macaulay、David Thomas、Sally-Anne Thompson、Keith A. Wafford、José L. Castro

  DOI：10.1021/jm040883v

  日期：2005.3.1

  We have previously identified the 7,8,9,10-tetrahydro-7,10-ethano-1,2,4-triazolo[3,4-a]phthalazine (1) as a potent partial agonist for the alpha(3) receptor subtype with 5-fold selectivity in binding affinity over alpha(1). This paper describes a detailed investigation of the substituents on this core structure at both the 3- and 6-positions. Despite evaluating a wide range of groups, the maximum selectivity

  我们之前已经确定了7,8,9,10-四氢-7,10-乙醇-1,2,4-三唑并[3,4-a]酞嗪（1）是α（3）的有效部分激动剂。受体亚型，对α（1）的结合亲和力具有5倍的选择性。本文描述了在此核心结构的3位和6位上的取代基的详细研究。尽管评估了广泛的组，但相对于alpha（1）亚型，对alpha（3）亚型的亲和力可达到的最大选择性是12倍（对于57）。尽管大多数类似物在功效上均未显示选择性，但一些类似物确实在α（1）处表现出部分激动作用，而在α（3）处表现出拮抗作用（例如25和75）。但是，测试了两个类似物（93和96），它们都在6位上有三唑取代基，显示出对alpha（3）亚型的疗效明显高于alpha（1）亚型。这是该系列中可以在所需方向上实现选择性的第一个迹象。
• [EN] 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] 7-OXO-6-(SULFOOXY)-1,6-DIAZABICYCLO[3.2.1] OCTANE CONTENANT DES COMPOSÉS ET LEUR UTILISATION DANS LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：WOCKHARDT LTD

  公开号：WO2017081615A1

  公开（公告）日：2017-05-18

  Compounds of Formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof, their preparation, and use in treating a bacterial infection are disclosed.

  化合物的公式（I）或其立体异构体或药学上可接受的盐，其制备以及在治疗细菌感染中的用途被披露。
• 1-substituted-2-(N-pheny
  申请人：NeuroSearch A/S

  公开号：US05296493A1

  公开（公告）日：1994-03-22

  The present patent application discloses compounds of the formula ##STR1## wherein R.sup.1 is C.sub.1-10 saturated or unsaturated alkyl; or ##STR2## wherein R'" is H or ##STR3## R.sup.2 is phenyl which is unsubstituted or substituted one or more times with halogen, CF.sub.3, C.sub.1-6 -alkoxy, NO.sub.2, CO.sub.2 --C.sub.1-6 -alkyl, methyl; benzyl which may be substituted one or more times with halogen, CF.sub.3, C.sub.1-6 -alkoxy, NO.sub.2, CO.sub.2 --C.sub.1-6 -alkyl, methyl; pyridyl; or cyclohexyl; R.sup.3 phenyl which is unsubstituted or substituted one or more times with halogen, CF.sub.3, C.sub.1-6 -alkoxy, NO.sub.2, CO.sub.2 --C.sub.1-6 -alkyl, methyl; naphthyl which may be substituted one or more times with halogen, CF.sub.3, C.sub.1-6 -alkoxy, NO.sub.2, CO.sub.2 --C.sub.1-6 -alkyl, methyl; pyridyl; C.sub.1-6 unsaturated alkyl; furanyl; R.sup.4 is H, C.sub.1-6 -alkyl, or benzyl; or ##STR4## together form ##STR5## R' and R" are each hydrogen or together form an extra benzo ring; and wherein the dotted line represents an optional extra bond between the two carbon atoms designated .alpha. and .beta., or a pharmaceutically-acceptable addition salt thereof. The compounds are useful as pharmaceuticals, for example in the treatment of Ca overload in brain cells.

  本专利申请公开了以下式化合物：其中R.sup.1为C.sub.1-10饱和或不饱和烷基；或其中R'"为H或其中R.sup.2为苯基，未取代或取代一次或多次的卤素、CF.sub.3、C.sub.1-6-烷氧基、NO.sub.2、CO.sub.2--C.sub.1-6-烷基、甲基；苄基，可能取代一次或多次的卤素、CF.sub.3、C.sub.1-6-烷氧基、NO.sub.2、CO.sub.2--C.sub.1-6-烷基、甲基；吡啶基；或环己基；R.sup.3为苯基，未取代或取代一次或多次的卤素、CF.sub.3、C.sub.1-6-烷氧基、NO.sub.2、CO.sub.2--C.sub.1-6-烷基、甲基；萘基，可能取代一次或多次的卤素、CF.sub.3、C.sub.1-6-烷氧基、NO.sub.2、CO.sub.2--C.sub.1-6-烷基、甲基；吡啶基；C.sub.1-6不饱和烷基；呋喃基；R.sup.4为H、C.sub.1-6-烷基或苄基；或者共同形成；R'和R"各为氢或共同形成额外的苯环；虚线代表两个指定的碳原子之间的可选额外键，或其药用接受的加盐物。这些化合物可用作药物，例如用于治疗脑细胞中的钙超载。
• Monomers and polymers carrying imidazole and benzimidazole groupings, and proton exchange membrane containing the same for the production of a fuel cell
  申请人：Glipa Xavier

  公开号：US08859160B2

  公开（公告）日：2014-10-14

  The invention relates to a monomer (6, 14) carrying an imidazole-type heterocycle (3). According to the invention, the chemical structure of said monomer (6, 14) comprises at least one unit of formula (I) wherein R1 comprises an alkenyl grouping and R2 comprises a grouping for protecting one of the nitrogen atoms of the heterocycle. The invention also relates to a monomer carrying a benzimidazole-type heterocycle, and to protected polymers obtained from said monomers, deprotected polymers produced by the protected polymers, a proton exchange membrane based on deprotected polymers, and a fuel cell provided with said membrane. Furthermore, the invention relates to methods for producing the above-mentioned monomers and polymers.

  该发明涉及一种携带咪唑类杂环（3）的单体（6, 14）。根据该发明，所述单体（6, 14）的化学结构包括至少一个符合式（I）的单元，其中R1包括烯基基团，R2包括用于保护杂环中的一个氮原子的基团。该发明还涉及携带苯并咪唑类杂环的单体，以及从所述单体获得的受保护聚合物，由受保护聚合物产生的去保护聚合物，基于去保护聚合物的质子交换膜，以及配备该膜的燃料电池。此外，该发明还涉及生产上述单体和聚合物的方法。
• Synthesis and properties of new fluorinated polymers bearing pendant imidazole groups for fuel cell membranes operating over a broad relative humidity range
  作者：Guillaume Frutsaert、Louis Delon、Ghislain David、Bruno Améduri、Deborah J. Jones、Xavier Glipa、Jacques Rozière

  DOI：10.1002/pola.23763

  日期：2010.1.1

  New alternating copolymers comprising a chlorotrifluorinated backbone and imidazole‐terminated pendant ethylene oxide groups have been prepared with a view to their use as a component of proton‐conducting membranes in polymer electrolyte fuel cells. A vinyl ether containing an imidazole (Imi) function protected by a benzyl group (BVI) was first synthesized in a three‐step reaction. It was then copolymerized

  为了将它们用作聚合物电解质燃料电池中质子传导膜的组分，已经制备了包含氯三氟主链和咪唑封端的环氧乙烷侧基的新型交替共聚物。首先通过三步反应合成了一个具有被苄基（BVI）保护的咪唑（Imi）官能团的乙烯基醚。然后通过常规的自由基共聚将其与三氟氯乙烯（CTFE）溶液共聚，从而以高收率交替使用聚（BVI-alt-CTFE）共聚物。在氢气下对苄基进行脱保护产生了三氟化氯聚（Imi-alt-CTFE）共聚物。该聚合物随后用于与磺化聚醚醚酮（sPEEK）形成共混膜。在40-70°C时为-1，对于富含聚（Imi-alt-CTFE）的共混膜而言，它几乎不受30％至100％之间的相对湿度的影响。据推测，聚合物和膜组成有利于将微结构相分离成三氟氯聚合物主链结构域和咪唑基团聚集的区域。©2009 Wiley Periodicals，Inc. J Polym Sci A部分：Polym Chem 48：223–231，2010年